KDR and neoplasm: Bevacizumab is a humanized monoclonal antibody against VEGF, which can block the binding of VEGF to VEGFR and thus reduce tumor angiogenesis.2The phase III study of nonsquamous non‐small cell lung cancer in China showed that compared with patients receiving chemotherapy alone, the median progressive survival time of patients receiving first‐line therapy of bevacizumab combined with paclitaxel and carboplatin was 2.7 months longer (9.2 months vs. 6.5 months).